Preconcentration of rifampicin prior to its efficient spectroscopic determination in the wastewater samples based on a nonionic surfactant

Every year, tuberculosis affects the lungs of millions of people and rifampicin is the commonly used medicine for its treatment due to its antibiotic nature. The frequent use of rifampicin may lead to its increased concentration in the water resources. This research work is focused on the cloud point extraction (CPE) procedure for the preconcentration of rifampicin prior to its determination in water. The UV/vis spectrophotometric method was adapted for the measurement of rifampicin content after the phase separation. Triton-X 100 was used as the nonionic surfactant which contains hydrophilic polyethylene chain feasible for the extraction of analyte. Various analytical parameters that can affect the extraction efficacy were optimized to achieve linearity of the proposed method in the concentration range of 3.54–81.41 mgL^–1. The Limit of detection and quantification were 1.261 and 4.212 mgL^–1, respectively. The Preconcentration factor was 40 with relative standard deviation (%RSD) of 2.504%. The standard addition methodology was adopted for the validation of this procedure and effectively applied for the determination of rifampicin in real wastewater samples.     

Potent anti-platelet constituents from Centaurea iberica

New naturally occurring nitrogenous compounds 1 and 2, along with a new dimeric lignan glucoside 3, have been isolated from the ethyl acetate soluble fraction of Centaurea iberica. Their structures have been elucidated through spectroscopic techniques. All the isolated compounds showed significant platelet aggregation inhibition.     

Synthesis,Crystal Structure and Antimicrobial Activity of Ethyl 2-（1-cyclohexyl-4-phenyl-1H-1,2,3-triazol-5-yl）-2-oxoacetate

A novel 1,4,5-trisubstituted 1,2,3-triazole(C18H21N3O3) was synthesized by a one-pot three component reaction of 1-azidocyclohexane, 1-copper(I) phenylethyne and ethoxalyl chloride at room temperature. The molecular structure was determined by single-crystal X-ray analysis. The compound crystallizes in the monoclinic system, space group P21/n with a = 12.8167(9), b = 8.0966(6), c = 16.7079(9) , β = 98.716(2)o, Z = 4 and V = 1713.8(2). In the crystal, the molecules are related by inversion and paired into dimers via C–H···O and C–O···C interactions involving(oxo) acetate groups. Furthermore, X-ray analysis results are compared with the optimized structure computed by using B3 LYP method with 6-311 G basis set. The calculated results showed that optimized geometry can well reproduce the crystal structure parameters. The bioassay results indicate that the compound has good antibacterial and antifungal activities.     

含羧基或酯基的新型二氧代氮杂茂并[3',4'-d]异(噁)唑衍生物的合成及其生物活性

在三乙胺的作用下,N-取代苯基-马来酰亚胺分别与α-氯代肟基乙酸和α-氯代肟基乙酸乙酯发生1,3-偶极环加成反应,合成了14种新型5-芳基-3a,6a-二氢-4,6-二氧代氮杂茂并[3',4'-d]异(噁)唑-3-甲酸衍生物(3a～3g)和5-芳基-3a,6a-二氢-4,6-二氧代氮杂茂并[3',4'-d]异(噁)唑-3-甲酸乙酯衍生物(4a～4g),其结构经1H NMR、IR和元素分析测试技术得以表征.对化合物进行了初步生物活性测试.结果表明,化合物3a、3b和3c样品浓度为10 μmoL/L时.对人白血病细胞生长的抑制率均为100%.化合物3d、3e和化合物4a、4d、4e对细胞分裂周期磷酸酯酶Cdc25A具有不同程度的抑制作用:当质量浓度为2×10-5 g/mL时,其抑制率分别为61.47%、66.23%、18.92%、22.49%和56.43%.并探讨了其构效关系.